• 1
    Alemany S, Arias B, Aguilera M et al. Childhood abuse, the BDNF-Val66Met polymorphism and adult psychotic-like experiences. Br J Psychiatry 2011;199:3842.
  • 2
    Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 2012;9:17.
  • 3
    Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009;39:17995.
  • 4
    Johns LC, Van Os J. The continuity of psychotic experiences in the general population. Clin Psychol Rev 2001;21:112541.
  • 5
    Henquet C, Murray R, Linszen D, Van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005;31:60812.
  • 6
    Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med 2012;42:13218.
  • 7
    Skinner R, Conlon L, Gibbons D, Mcdonald C. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care. Acta Psychiatr Scand 2011;123:217.
  • 8
    Janssen I, Krabbendam L, Bak M et al. Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr Scand 2004;109:3845.
  • 9
    Read J, Van Os J, Morrison AP, Ross CA. Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. Acta Psychiatr Scand 2005;112:33050.
  • 10
    Varese F, Smeets F, Drukker M et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 2012;38:6617.
  • 11
    Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Facorro B. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des 2012;18:502435.
  • 12
    Harley M, Kelleher I, Clarke M et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med 2010;40:162734.
  • 13
    Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull 2008;34:5805.
  • 14
    Houston JE, Murphy J, Shevlin M, Adamson G. Cannabis use and psychosis: re-visiting the role of childhood trauma. Psychol Med 2011;18:110.
  • 15
    Konings M, Stefanis N, Kuepper R et al. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med 2012;42:14959.
  • 16
    Gessa GL, Melis M, Muntoni AL, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998;341:3944.
  • 17
    Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:1323.
  • 18
    Kuepper R, Henquet C, Lieb R, Wittchen HU, Van Os J. Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr Res 2011;131:2623.
  • 19
    Collip D, Van Winkel R, Peerbooms O et al. COMT Val158Met-stress interaction in psychosis: role of background psychosis risk. CNS Neurosci Ther 2011;17:61219.
  • 20
    Peerbooms O, Rutten BP, Collip D et al. Evidence that interactive effects of COMT and MTHFR moderate psychotic response to environmental stress. Acta Psychiatr Scand 2012;125:24756.
  • 21
    Van Winkel R, Henquet C, Rosa A et al. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1017.
  • 22
    Chen J, Lipska BK, Halim N et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:80721.
  • 23
    Meyer-Lindenberg A, Kohn PD, Kolachana B et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005;8:5946.
  • 24
    Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999;51:593628.
  • 25
    Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:111727.
  • 26
    Estrada G, Fatjo-Vilas M, Munoz MJ et al. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. Acta Psychiatr Scand 2011;123:48592.
  • 27
    Henquet C, Rosa A, Delespaul P et al. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of ‘switching on’ hallucinations in the flow of daily life. Acta Psychiatr Scand 2009;119:15660.
  • 28
    Decoster J, Van Os J, Myin-Germeys I, De Hert M, Van Winkel R. Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions. Curr Pharm Des 2012;18:501523.
  • 29
    Savitz J, Van Der Merwe L, Newman TK, Stein DJ, Ramesar R. Catechol-o-methyltransferase genotype and childhood trauma may interact to impact schizotypal personality traits. Behav Genet 2010;40:41523.
  • 30
    Aguilera M, Arias B, Wichers M et al. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol Med 2009;39:142532.
  • 31
    Arias B, Aguilera M, Moya J et al. The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxiety-related traits. Acta Psychiatr Scand 2012;125:194202.
  • 32
    First MB, Spitzer RL, Williams JBW, Gibbon M. Structured clinical interview of DSM-IV disorders-Research Version (SCID-RV). Washington, DC: American Psychiatric Association, 1997.
  • 33
    Maxwell M. Family interview for genetic studies (FIGS): manual for FIGS. Bethesda, MD: Clinical Neurogenetics Branch, Intramural Research Program, National Institutde of Mental Health, 1992.
  • 34
    Stefanis NC, Hanssen M, Smirnis NK et al. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med 2002;32:34758.
  • 35
    Konings M, Bak M, Hanssen M, Van Os J, Krabbendam L. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr Scand 2006;114:5561.
  • 36
    Ros-Morente A, Vilagra-Ruiz R, Rodriguez-Hansen G, Wigman JH, Barrantes-Vidal N. Process of adaptation to Spanish of the Community Assessment of Psychic Experiences (CAPE). Actas Esp Psiquiatr 2011;39:95105.
  • 37
    Bernstein DPFL. Childhood Trauma Questionnaire: a Retrospective Self-report. San Antonio: The Psychological Corporation, 1998.
  • 38
    Bernstein DP, Stein JA, Newcomb MD et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl 2003;27:16990.
  • 39
    Raine A, Benishay D. The SPQ-B: a brief screening instrument for schyzotypal personality disorder. J Personal Disord 1995;9:34655.
  • 40
    Spielberg CG, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1970.
  • 41
    Gauderman W, Morrison J. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. http:/ 2006.
  • 42
    Nuevo R, Chatterji S, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL. The continuum of psychotic symptoms in the general population: a cross-national study. Schizophr Bull 2012;38:47585.
  • 43
    Kokkevi A, Nic Gabhainn S, Spyropoulou M. Early initiation of cannabis use: a cross-national European perspective. J Adolesc Health 2006;39:71219.
  • 44
    Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004;99:133341.
  • 45
    Compton MT, Furman AC, Kaslow NJ. Preliminary evidence of an association between childhood abuse and cannabis dependence among African American first-episode schizophrenia-spectrum disorder patients. Drug Alcohol Depend 2004;76:31116.
  • 46
    Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008;34:111121.
  • 47
    Collip D, Myin-Germeys I, Van Os J. Does the concept of “sensitization” provide a plausible mechanism for the putative link between the environment and schizophrenia? Schizophr Bull 2008;34:2205.
  • 48
    Zammit S, Owen MJ, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry 2011;199:3805.
  • 49
    Maclean KI, Littleton JM. Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol. Eur J Pharmacol 1977;41:17182.
  • 50
    Di Forti M. Why do psychotic patients take cannabis? Psychol Med 2008;38:10712.
  • 51
    Zammit S, Wiles N, Lewis G. The study of gene-environment interactions in psychiatry: limited gains at a substantial cost? Psychol Med 2010;40:71116.
  • 52
    Munafo MR, Flint J. Replication and heterogeneity in gene x environment interaction studies. Int J Neuropsychopharmacol 2009;12:7279.
  • 53
    Duncan LE, Keller MC. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am J Psychiatry 2011;168:10419.
  • 54
    Rutter M, Moffitt TE, Caspi A. Gene-environment interplay and psychopathology: multiple varieties but real effects. J Child Psychol Psychiatry 2006;47:22661.
  • 55
    Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41:36172.
  • 56
    McClelland GH, Judd CM. Statistical difficulties of detecting interactions and moderator effects. Psychol Bull 1993;114:37690.
  • 57
    Gerdner A, Allgulander C. Psychometric properties of the Swedish version of the Childhood Trauma Questionnaire-Short Form (CTQ-SF). Nord J Psychiatry 2009;63:16070.
  • 58
    Thombs BD, Bernstein DP, Lobbestael J, Arntz A. A validation study of the Dutch Childhood Trauma Questionnaire-Short Form: factor structure, reliability, and known-groups validity. Child Abuse Negl 2009;33:51823.
  • 59
    Di Forti M, Morgan C, Dazzan P et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;195:48891.
  • 60
    Dragt S, Nieman DH, Schultze-Lutter F et al. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand 2012;125:4553.